To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06545955
Title A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer (ABLE-22)
Acronym ABLE-22
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ferring Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Ferring Investigational Site RECRUITING Fresno California 93720 United States Details
Ferring Investigational Site RECRUITING Los Angeles California 90017 United States Details
Ferring Investigational Site RECRUITING New Haven Connecticut 06519 United States Details
Ferring Investigational Site RECRUITING Atlanta Georgia 30322 United States Details
Ferring Investigational Site RECRUITING Boise Idaho 83702 United States Details
Ferring Investigational Site RECRUITING Troy Michigan 48084 United States Details
Ferring Investigational Site RECRUITING Poughkeepsie New York 12603 United States Details
Ferring Investigational Site RECRUITING Bala-Cynwyd Pennsylvania 19004 United States Details
Ferring Investigational Site RECRUITING Myrtle Beach South Carolina 29572 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field